ESCAPE30: major developments in our CDMO services
ESCAPE30: excellence in CDMO services for antibodies and therapeutic proteins in Europe, by 2030.
In November 2022, the entire management team of LFB BIOMANUFACTURING met to set a trajectory for the company and define our long-term priorities and development strategy. This trajectory was named “ESCAPE30”.
“Escape30: An ambitious vision to strengthen national sovereignty and meet patient needs for biomedicinal products worldwide.”
At LFB BIOMANUFACTURING, we aim for Excellence in our CDMO Services for Antibodies and Therapeutic Proteins in Europe, by 2030, to further strengthen French sovereignty in the field.
We leverage our strong foundations and scientific heritage to help meet the needs of patients globally, providing CDMO service excellence in the development and GMP (BPF, French Good Manufacturing Practice) manufacturing of innovative biomedicinal products.
LFB Biomanufacturing's CDMO innovation strategy: service, innovation, impact
LFB Biomanufacturing on a positive trajectory towards its goal of making itself one of the elite CDMOs in Europe
♦ Flawless execution
♦ Strategic site investments
♦ Accelerated business development
♦ Excellent customer portfolio
♦ Introduction of new products
♦ Short-term strategic partners
♦ Restructuring of the one-stop shop
♦ Additional therapeutic methods
♦ Long-term strategic partnerships